Group 1: Financial Performance - In Q1 2025, the company achieved revenue of CNY 2.002 billion, a year-on-year increase of 32.14% [2] - The net profit attributable to shareholders was CNY 0.39 billion, up 39.30% year-on-year [2] - The non-recurring net profit attributable to shareholders was CNY 0.22 billion, reflecting a growth of 20.80% [2] Group 2: Product Performance - The shipment volume of battery chemicals significantly increased, driven by a competitive market for lithium battery materials [2] - The electrolyte business saw a nearly 80% year-on-year increase in shipment volume, although prices experienced a decline [5] - The overseas sales of electrolytes accounted for nearly 20% of total sales in Q1 2025 [6] Group 3: Market Outlook - The demand for fluorinated liquids is expected to grow, particularly due to the increasing installation of wafer fabs [3] - The company anticipates stable growth in the fluorinated liquid market, supported by its unique technological advantages [3] - The emerging industries such as new energy and data centers are expected to drive demand for related fluorine materials [2] Group 4: Project Updates - The Haidefu project showed improved sales performance and reduced losses in Q1 2025, with expectations for better performance than in 2024 [4] - The Malaysian electrolyte project is in the early approval and planning stages, with completion expected within two years [7] - The acquisition of Jiangxi Shilei has resulted in good operational performance, with full production capacity achieved [8] Group 5: Strategic Initiatives - The company plans to increase R&D investment to expand its product line and enhance market share [3] - The 2023 stock incentive plan is expected to incur expenses of approximately CNY 60-70 million, to be recognized quarterly [8]

Summary of the Conference Call for Xinjubang Company Overview - **Company**: Xinjubang - **Industry**: Lithium battery materials, fluorochemical products, capacitor chemicals Key Points and Arguments 1. Sales and Revenue Performance - In Q1 2025, Xinjubang achieved revenue of 2.002 billion yuan, a year-on-year increase of 32.14% [3] - Net profit attributable to shareholders was 230 million yuan, up 39.3% year-on-year [3] - Lithium battery business saw a significant sales increase of approximately 70-80% year-on-year, although overall revenue was pressured by price declines [2][5] 2. Growth Drivers - The main growth drivers were fluorochemical products and capacitor chemicals, both achieving double-digit growth in sales and profit contributions [2][6] - The semiconductor and cosmetics sectors performed well, albeit from a smaller base [2][6] 3. International Sales and Market Strategy - Overseas sales accounted for approximately 20-30% of electrolyte sales, with significant contributions from fluorochemical and capacitor chemicals [10][12] - The company exports primarily through its European factory in Poland, mitigating short-term tariff impacts [5][10] - The Malaysian factory is in the planning stage, with a construction period of about two years, and will adjust its pace based on market demand [10] 4. Product Development and Market Position - Following 3M's exit from the market, there may be inventory accumulation among downstream customers for organic fluorine products [7] - The company is expanding its product range, including cooling and cleaning products, to drive business growth [7][8] 5. Price Stability and Market Outlook - Current prices for fluorinated liquids are stable, with short-term price declines unlikely due to the slowdown in wafer factory growth [12] - Long-term trends suggest gradual price decreases as production increases [12] 6. Future Performance Expectations - The company aims for a profit target of 1.1 billion yuan for 2025, with expectations for better performance in the second half of the year [4][15] - The company maintains an optimistic outlook for the fluorochemical sector, which is less affected by tariff policies [4][15] 7. Challenges and Risks - The potential impact of U.S. tariffs on electrolyte exports remains uncertain, although currently manageable [13][20] - The company is closely monitoring the evolving market conditions and regulatory environment, particularly regarding environmental regulations affecting competitors like 3M [11][16] 8. Strategic Collaborations and Innovations - The capacitor chemicals business is expected to remain a core growth pillar, supported by leading technology and stable quality [3][21] - Ongoing R&D collaborations, such as with Jianghai for MLCC conductive polymer materials, are still in the development phase [21] 9. Stock Incentive Plans - The company confirmed stock incentive expenses for 2023 and plans to allocate approximately 60 million yuan for the new incentive plan starting in May 2025 [19] 10. Overall Market Position - Xinjubang's performance shows resilience compared to peers, with stable growth in fluorochemical and capacitor businesses despite challenges in electrolyte profitability [22] This summary encapsulates the key insights from the conference call, highlighting the company's performance, growth strategies, market dynamics, and future outlook.

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's Q1 2025 performance met market expectations, with revenue of 2 billion yuan, a year-on-year increase of 32.1% and a quarter-on-quarter decrease of 8.1%. The net profit attributable to shareholders was 230 million yuan, reflecting a year-on-year increase of 39.3% and a quarter-on-quarter decrease of 4.5% [8] - The report anticipates a turning point in fluorochemical and electrolyte segments in 2025, driven by high growth in electrolyte shipments and increasing overseas orders [8] - The company has acquired a 42% stake in Shilei, which is expected to enable self-supply of hexafluoropropylene, meeting 40-50% of its electrolyte demand [8] Financial Forecasts - Total revenue is projected to grow from 7,484 million yuan in 2023 to 16,678 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 27.95% [1] - Net profit attributable to shareholders is expected to increase from 1,011.07 million yuan in 2023 to 2,005.03 million yuan in 2027, reflecting a CAGR of about 23.97% [1] - The report forecasts earnings per share (EPS) to rise from 1.34 yuan in 2023 to 2.66 yuan in 2027, with a corresponding price-to-earnings (P/E) ratio of 25x for 2025 [1][8]

Investment Rating - The investment rating for the company is "Buy" [4] Core Views - The company reported a revenue of 2.002 billion yuan in Q1 2025, representing a year-on-year increase of 32.14% and a quarter-on-quarter decrease of 8.13%. The net profit attributable to the parent company was 230 million yuan, up 39.3% year-on-year but down 4.45% quarter-on-quarter [1] - The growth in organic fluorine and the increase in electrolyte volume, despite a price drop, have contributed to the company's resilient performance [2] - The company is deepening its international market presence and expects accelerated growth in organic fluorine products, particularly following the exit of 3M from the fluorinated liquid production [3] Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 2.002 billion yuan, a 32% increase year-on-year, driven by the growth in capacitor chemicals, electrolytes, and organic fluorine sales [2] - The average price of electrolytes in Q1 2025 was 19,400 yuan per ton, a decrease of 7.7% year-on-year, while the gross profit margin was 24.55%, down 2.7 percentage points year-on-year [2] Market Position and Strategy - The company has invested in key raw materials such as lithium hexafluorophosphate and is expanding its global footprint with a new electrolyte base in Malaysia, enhancing its ability to respond to international customer demands [3] - The company anticipates significant growth in its fluorinated liquid products due to the closure of 3M's production capacity [3] Profit Forecast and Valuation - The projected net profit attributable to the parent company for 2025-2027 is 1.198 billion, 1.541 billion, and 1.949 billion yuan, respectively, with corresponding P/E ratios of 19.1, 14.8, and 11.7 [4]

| 证券代码：300037 | 证券简称：新宙邦 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：123158 | 债券简称：宙邦转债 | | 深圳新宙邦科技股份有限公司 关于控股子公司向银行申请项目贷款并由公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳新宙邦科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第六届董事会第二十二次会议、第六届监事会第二十次会议，审议通过了《关 于控股子公司向银行申请项目贷款并由公司提供担保的议案》，具体情况如下： 一、担保情况概述 公司于2024年12月26日召开第六届董事会第十八次会议、第六届监事会第十 七次会议，审议通过了《关于控股子公司投资建设海德福年产5000吨高性能氟材 料（1.5期）项目的议案》，为满足公司控股子公司福建海德福新材料有限公司（以 下简称"海德福"）"海德福年产5000吨高性能氟材料（1.5期）"项目建设发展 资金需要，顺利推进海德福年产5000吨高性能氟材料（1.5期）项目的实施，海德 福拟向银行申请项目贷 ...

| 证券代码：300037 | 证券简称：新宙邦 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123158 | 债券简称：宙邦转债 | | 深圳新宙邦科技股份有限公司 关于投资建设马来西亚诺莱特电子化学品项目的公告 一、投资概况 1、深圳新宙邦科技股份有限公司（以下简称"公司"）拟以全资孙公司 Novolyte Technology Sdn. Bhd.（以下简称"马来西亚诺莱特"）为项目实施主体， 在马来西亚吉打州建设电子化学品生产基地，项目计划总投资不超过 2,600 万美 元（项目总投资额以实际投资建设情况为准）。 2、本次投资建设的资金来源为公司自有及自筹资金，后续如需改变资金来 源，需根据规定履行相应审批程序。 3、本次对外投资不涉及关联交易，不构成中国证监会《上市公司重大资产 重组管理办法》规定的重大资产重组情形。根据《深圳证券交易所创业板股票上 市规则》《公司章程》等相关规定，本次投资事项无需提交公司股东大会审议。 二、项目基本情况 1 1、项目名称：马来西亚诺莱特电子化学品项目（以下简称"本项目"） 2、投资建设地点：马来西亚吉打州 3、实施主体：马 ...

2025年第一季度报告披露提示性公告 深圳新宙邦科技股份有限公司 | 证券代码：300037 | 证券简称：新宙邦 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：123158 | 债券简称：宙邦转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 4 月 29 日 特此公告。 深圳新宙邦科技股份有限公司董事会 特别提示：《公司2025年第一季度报告》已于2025年4月29日在中国证监会 指定的创业板信息披露网站上披露，敬请投资者注意查阅。 2025年4月28日，深圳新宙邦科技股份有限公司（以下简称"公司"）召开第 六届董事会第二十二次会议，审议通过了《关于<公司2025年第一季度报告>的 议案》。《公司2025年第一季度报告》于2025年4月29日在中国证监会指定的创业 板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露。敬请广大投资 者注意查阅。 ...

法律意见书 二〇二五年四月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦（深圳）律师事务所 关于深圳新宙邦科技股份有限公司 2025 年第一次临时股东大会的 北京市中伦（深圳）律师事务所 关于深圳新宙邦科技股份有限公司 法律意见书 致：深圳新宙邦科技股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《上市公司股东大 会规则》（下称"《股东大会规则》"）和《深圳新宙邦科技股份有限公司章程》 （下称"《公司章程》"）的规定，北京市中伦（深圳）律师事务所（下称"本所"） 接受深 ...

| 证券代码：300037 | 证券简称：新宙邦 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：123158 | 债券简称：宙邦转债 | | 深圳新宙邦科技股份有限公司 2025年第一次临时股东大会决议公告 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 4 月 28 日 9：15—9：25，9：30—11:30 和 13：00—15：00 通过深圳证券交易所互联网投票系统投票的具体时间为2025年4月28日9： 15 至 15：00 任意时间 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决议案的情况； 2、本次股东大会不涉及变更前次股东大会决议的情况； 3、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间：2025 年 4 月 28 日（星期一）14:00 2、网络投票时间： 3、现场会议召开地点：深圳市坪山区昌业路深圳新宙邦科技大厦 16 层会议 室 4、会议召集人：公司第六届董事 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300037 | 证券简称：新宙邦 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：123158 | 债券简称：宙邦转债 | | 深圳新宙邦科技股份有限公司 第六届监事会第二十次会议决议公告 深圳新宙邦科技股份有限公司（以下简称"公司"）第六届监事会第二十次 会议于 2025 年 4 月 28 日在公司会议室以通讯方式召开。本次监事会会议通知已 于 2025 年 4 月 22 日以电子邮件方式发出。本次监事会应参与表决监事 3 人，实 际参与表决监事 3 人，公司董事会秘书贺靖策先生列席会议。会议由公司监事会 主席张桂文女士召集并主持。本次会议的召集、召开符合有关法律、法规和《公 司章程》的规定。 经表决形成如下决议： 一、审议通过了《关于<公司 2025 年第一季度报告>的议案》 经审核，公司监事会认为：《公司 2025 年第一季度报告》的编制和审议程 序符合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真 实、准确、完整地反映了公司 20 ...